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The study consisted of a cost-minimisation analysis since the findings from a multicentre randomised phase III trial showed that
pegylated liposomal doxorubicin hydrochloride was at least as efficacious as topotecan. An economic model from the Spanish
hospitals perspective was constructed to compare the costs derived from the treatment using both drugs in patients with recurrent
epithelial ovarian cancer who failed a first-line platinum-containing regimen. The cost evaluation included direct medical costs: drug,
drug administration and costs of managing adverse events. Estimation of resources used in managing adverse events was made
retrospectively through an expert panel. Results obtained per patient were: cost of drug and administration, 8647.70 euros for
pegylated liposomal doxorubicin hydrochloride and 8519.94 euros for topotecan, while cost of managing adverse events was 967.02
euros in the pegylated liposomal doxorubicin hydrochloride arm and 3304.75 euros for topotecan. The total cost per patient was
therefore estimated to be 9614.72 euros for pegylated liposomal doxorubicin hydrochloride and 11824.69 euros for topotecan,
showing that pegylated liposomal doxorubicin hydrochloride produces a cost saving of 2209.97 euros per patient in comparison to
topotecan. Sensitivity analyses verified the robustness of the results. These findings suggest that pegylated liposomal doxorubicin
hydrochloride is an efficient therapy and can be used as a cost-saving option for treatment of patients with recurrent epithelial ovarian
cancer who have failed a first-line platinum-containing regimen.
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Ovarian cancer is the sixth most common form of cancer
worldwide and is the leading cause of cancer deaths of the
gynaecological tumours (Landis et al, 1998). In Spain, ovarian
cancer has an annual incidence of 7.9 per 100000 women, and an
annual death rate of 3.7 per 100000 women (Borra ´s et al, 1997).
Due to the often asymptomatic nature of the early stages of disease,
many cases of ovarian cancer have a very poor diagnosis and are
not detected until the advanced stages, which suggest that a low
survival rate since 5-year survival rates for women in advanced
stages of the disease are only around 30% (Gore, 1999, pp 76–90).
In advanced stage disease, standard care consists of surgical
debulking followed by platinum-based therapy. Recent studies
have helped to form the opinion that these advanced stage patients
may be treated with paclitaxel and platinum therapy, due to
increased response and survival rates with the combination
(McGuire et al, 1996; Du Bois et al, 1999; Ozols et al, 1999; Piccart
et al, 2000; Neijt et al, 2000). In spite of these improvements, 50–
75% of patients with advanced disease will ultimately relapse
(Hager et al, 2001). Some of these patients are candidates for
retreatment with platinum regimens, but patients who do not
respond or who relapse are much less likely to respond to
subsequent chemotherapy regimens. There is a need for other
effective treatments for platinum-resistant tumours.
Substantial clinical activity with pegylated liposomal doxorubi-
cin hydrochloride (PLD; Caelyx/Doxil
s) has been shown in
patients refractory to paclitaxel and platinum-based chemotherapy
(Gordon et al, 2001). Pegylated liposomal doxorubicin hydro-
chloride is a pegylated liposomal formulation of doxorubicin
hydrochloride, which results in an altered kinetic profile,
extending the half-life to 74h. It is thought that the pegylated
liposomal formulation may improve specificity of delivery to
tumours, decreasing absorption by normal tissues, and may
decrease many of the dose-limiting side effects of doxorubicin
(Goram et al, 2001).
Topotecan (T) is a topoisomerase I inhibitor approved in
Europe for the treatment of metastatic ovarian cancer after failure
of first-line or for subsequent retreatment. Topotecan produces
DNA damage in the presence of the nuclear enzyme topoisomerase
I, which relieves the strain in DNA supercoils during replication
and translation, and causes cell death by generating double-
stranded DNA breaks (Kollmannsberger et al, 1999).
Recent guidance from NICE in the UK recommends that either
PLD or T should be considered as options for the second-line (or
subsequent) treatment of women with advanced ovarian cancer Received 8 January 2003; revised 8 June 2003; accepted 29 June 2003
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lwhere the disease is initially resistant or refractory to first-line
platinum-based combination therapy or has become resistant
after successive courses of platinum-based combination therapy
(National Institute for Clinical Excellence, 2001, 2002).
A cost-minimisation analysis of PLD and T has been reported in
a previous study in the USA and the UK (Smith et al, 2002). The
objective of this analysis is to determine the most cost-efficient
therapy in the Spanish setting, since the clinical findings from a
multicentre randomised trial showed that PLD was at least as
efficacious as T (Gordon et al, 2001). An economic analysis has
been performed in the form of a cost-minimisation analysis, in
order to estimate and compare the costs associated with the two
alternatives, PLD and T in Spain.
MATERIALS AND METHODS
Analysis design
A cost-minimisation analysis is a type of pharmacoeconomic
analysis in which costs of two or more alternative therapies are
compared, and has as its central assumption that the clinical
outcomes of those therapies are equivalent. The goal is to find the
least expensive way of achieving the specific outcomes (Robinson,
1993; Basskin, 1998; Briggs and O’Brien, 2001).
This analysis was performed according to the findings of a
randomised phase III trial, comparing PLD vs T in patients with
recurrent epithelial ovarian cancer who failed a first-line platinum-
containing regimen (Gordon et al, 2001). Since the findings from
the clinical trial showed that PLD had overall comparable efficacy
with T, the pharmacoeconomic analysis has been performed as a
cost-minimisation analysis, wherein the costs of PLD and T are
compared.
Our analysis consisted in a pharmacoeconomic model that
allows simulations of complex clinical management to be made,
and which uses estimations taken from published data of efficacy,
tolerability and costs of the competing treatments. This model
permitted us to estimate the expected economic consequences of a
whole treatment process with PLD or T (Smith et al, 2002).
Clinical data
The randomised phase III trial explained above was a multicentre
study with sites both in Europe and North America. A total of 474
patients were treated (239 PLD and 235T). All patients had failed
first-line chemotherapy with a platinum-based regimen and
comprised the intent-to-treat population. Patients were stratified
prospectively for platinum sensitivity and bulky disease, and could
have received no more than one prior platinum-based regimen.
The study drug regimens consisted of either a 1h intravenous
infusion of PLD 50mgm
 2 every 28 days or T 1.5mgm
 2day
 1 as
a 30min infusion for five consecutive days every 21 days (Gordon
et al, 2001; Smith et al, 2002).
The results obtained suggest comparable efficacy between the
two drugs, PLD and T: the overall progression-free survival rates
were similar between the two arms (113 days in the PLD arm and
119 in the T (P¼0.095)); the overall response rates for PLD and T
were 19.7 and 17.0%, respectively (P¼0.390); median overall
survival times were 60 weeks for the subgroup of PLD and 56.7
weeks for T (P¼0.341). Data analysed in platinum-sensitive
patients demonstrated a statistically significant benefit with PLD
for progression-free survival (P¼0.037), with medians of 28.9
weeks for PLD vs 23.3 weeks for T. For overall survival, PLD was
significantly superior to T (P¼0.008), with a median of 108 vs 71.1
weeks. The platinum-refractory subgroup demonstrated a non-
statistically significant survival trend in favour of T (0.455). Severe
a haematologic toxicity was more common with T (Gordon et al,
2001).
Resource estimation perspective
Cost estimation for a pathology treated with any drug is made by
identification of the resources used in the process, measuring and
quantifying these resources and assigning a standard price to each
of these resources (in monetary units).
Usually, in this type of pharmacoeconomic analysis, only direct
medical costs are included, without taking into account indirect
and intangibles costs.
Three main categories of costs, derived from routine clinical
practice in the Spanish hospitals, were considered in the cost-
minimisation analysis:
  costs of the study drug;
  costs of drug administration (e.g. cost of outpatient visits,
infusions);
  costs of managing adverse events (e.g. cost of additional
medication, any associated hospitalisation).
To estimate the costs derived from each arm of the trial, the total
amount of study drug per patient, used during the clinical trial,
was calculated by multiplying each dose (mgm
 2) administered by
the patient’s surface area and summing overall doses administered.
The result was then multiplied by the cost of the study drug. The
cost for outpatient consultations (at the beginning of each
treatment cycle) and outpatient visits (for administration of each
dose) were also added. In each administration of T, the use of
antiemetic drugs (granisetron and tropisetron, in 66.7 and 33.3%
of patients, respectively, according to expert opinion) was also
required. Table 1 shows the amounts of study drug and cycles
(total and per patient) used to make these estimations (Gordon
et al, 2001; Smith et al, 2002).
The resources used to manage every adverse event were
measured for each drug, PLD and T. First, frequency of adverse
events by type and severity level for both drugs was analysed, as
shown in Table 2 (Gordon et al, 2001; Smith et al, 2002). Then, the
costs derived from the treatment of each type of adverse event in
each of their severity levels were determined. These results were
used to calculate the cost per adverse event and per patient. The
estimated cost for each adverse event type was then added to
obtain a total adverse event management cost per patient.
Cost sources. Expert opinion
Costs of study drugs (price ex-factory) and drugs to treat adverse
events were taken from the Spanish Catalogue of Medicinal
Products 2001. The unit costs of the procedures and tests included
in the analysis were collected from the Spanish Data Base of
Sanitary Costs 2001 (SOIKOS, 2001) and published literature. Costs
were collected in pesetas at 2001 values and converted to euros at
the official rate of 166.386pesetaseuro
 1.
Estimation of resource utilisation associated with treatments of
both PLD and T when managing adverse events was made in a
retrospective way through an expert panel, which participated for
quality assurance and validation purposes. This expert panel
consisted of three medical oncologists who usually treat ovarian
Table 1 Amounts of study drug and number of cycles (Gordon et al,
2001; Smith et al, 2002)
Total mg
drug used
Mg per
patient
Total
cycles
Cycles per
patient
Total
doses
PLD
(n¼239) 94447 395.18 1164 4.87 1164
Topotecan
(n¼235) 15653 66.60 1349 5.74 6673
PLD¼pegylated liposomal doxorubicin hydrochloride.
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lcancer in representative University Hospitals in Spain and two
health economists working in several meetings based on structured
questionnaires and discussion. Subsequent meetings between the
experts were held to define all resources used in diagnosis and
treatment of adverse events.
Adverse events
The nine adverse events included in this analysis were chosen on
the basis of patient perception, frequency and clinical importance,
and were the most significant according to the decision of the
expert panel based on health-care resource consumption at
hospitals. These were the same adverse events evaluated in a
previous analysis (Smith et al, 2002):
  Anaemia
  Thrombocytopenia
  Neutropenia
  Sepsis
  Fever
  Stomatitis/pharyngitis
  Nausea, vomiting
  Diarrhoea
  PPE: palmar-plantar erythrodysesthesia
Alopecia, one of the most important adverse events occurring in
the clinical trial that favoured PLD (Gordon et al, 2001), was
excluded from the analysis since Spanish hospitals (perspective
used) do not treat this adverse event in clinical practice. The panel
of experts made an estimation of resources used in the manage-
ment of adverse events, in terms of the following severity level:
  Mild (Grade I): signs or symptoms were noticed by patients but
easily tolerated. The event was not expected to have any
influence on the patient’s health or well-being, and it had little
clinical significance.
  Moderate (Grade 2): patient’s usual activities were altered
because of the event. It was of some concern to the patient’s
health or well-being, and may have required medical interven-
tion and/or close follow-up.
  Severe (Grade 3): the adverse event interfered considerably with
the patient’s usual activities and was of definite concern to the
patient and/or posed substantial risk to the patient’s health or
well-being. The event was likely to require medical intervention
and/or close follow-up and may have been incapacitating or life
threatening.
  Life threatening/fatal (Grade 4): the patient was incapacitated.
The event constituted a high risk to the patient’s immediate
health or well-being.
RESULTS
Base-case
Costs in euros used in the pharmacoeconomic analysis are shown
in Table 3 including cost of drug per mg, cost of the antiemetic
drugs required for T, cost of an outpatient visit and cost of an
outpatient consultation. Table 4 shows the estimation of costs
made by the expert panel when treating adverse events, which
increases as the severity level increases. Only anaemia has a grade
II severity level more costly to manage than the other grades due to
the use of erythropoietin, whereas grades III and IV were
considered to be treated with transfusions, which are less costly
than erythropoietin.
The final results are calculated in Table 5. Costs of the study
drug, drug administration, and management of each type of
adverse event were added to obtain a total cost per patient for both
arms of the study. These results show that the total cost of drug
plus administration does not differ substantially between PLD and
T, despite the cost of PLD being much higher. This is due to the
Table 2 Adverse event frequency by type and severity level in the two
treatment arms (Gordon et al, 2001; Smith et al, 2002)
Adverse event type Grade PLD n (%) Topotecan n (%)
Anemia Total 319 (100) 985 (100)
Grade I 199 (62) 363 (37)
Grade II 101 (32) 476 (48)
Grade III 18 (6) 134 (14)
Grade IV 1 (0) 12 (1)
Thrombocytopenia Total 71 (100) 944 (100)
Grade I 54 (76) 434 (46)
Grade II 14 (20) 272 (29)
Grade III 3 (4) 175 (19)
Grade IV 0 (0) 63 (7)
Neutropenia Total 311 (100) 1438 (100)
Grade I 153 (48) 296 (20)
Grade II 105 (35) 378 (26)
Grade III 42 (14) 427 (30)
Grade IV 11 (3) 337 (24)
Sepsis Total 4 (100) 17 (100)
Grade I 0 (0) 0 (0)
Grade II 1 (25) 5 (35)
Grade III 3 (75) 3 (15)
Grade IV 0 (0) 9 (50)
Fever Total 69 (100) 65 (100)
Grade I 36 (55) 31 (48)
Grade II 26 (42) 20 (31)
Grade III 2 (3) 8 (12)
Grade IV 0 (0) 5 (9)
Stomatitis/Pharyngitis Total 378 (100) 130 (100)
Grade I 202 (53) 91 (70)
Grade II 144 (38) 37 (28)
Grade III 31 (8) 2 (2)
Grade IV 1 (0) 0 (0)
Nausea/Vomiting Total 386 (100) 567 (100)
Grade I 236 (61) 333 (59)
Grade II 110 (28) 175 (31)
Grade III 37 (10) 51 (9)
Grade IV 3 (1) 8 (1)
Diarrhoea Total 74 (100) 126 (100)
Grade I 42 (57) 68 (54)
Grade II 26 (35) 47 (37)
Grade III 5 (7) 10 (8)
Grade IV 1 (1) 1 (1)
PPE Total 379 (100) 2 (100)
Grade I 195 (51) 2 (100)
Grade II 120 (32) 0 (0)
Grade III 62 (16) 0 (0)
Grade IV 2 (1) 0 (0)
PLD¼pegylated liposomal doxorubicin hydrochloride; PPE¼palmar-plantar ery-
throdysesthesia.
Table 3 Unitary costs (euros)
PLD Topotecan
Cost per mg 19.70 63.91
Antiemetic drugs NR 22.02
Outpatient visit 115.72
Outpatient consultation 61.32
PLD¼pegylated liposomal doxorubicin hydrochloride; NR¼not required.
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lmore frequent and thus more expensive administration necessary
with T. However, total medical costs are lower with PLD (9614.72
vs 11824.69euros), due to the fact that those adverse events that
are more frequent with T are more costly to manage, and add
significantly to the overall cost.
Sensitivity analysis
The uncertainty derived from the premises assumed in the study
need to be reviewed through a sensitivity analysis to confirm the
robustness of our results. Consequently, an analysis was conducted
to identify the impact that changes in the most significant variables
would have on the study conclusions.
(a) Increasing/reducing by 50% the length of hospitalisation and
the number of outpatient visits when managing adverse
events: these parameters were chosen because they are the
most influential in the cost of treating the most common
adverse events from PLD and T. To favour T, a 50% increase
was applied in the case of managing stomatitis/pharyngitis,
PPE and diarrhoea (the most important adverse events, in
terms of estimated costs values, in treatment with PLD), and
the cost of the rest of the adverse events was reduced by 50%
(more common in treatment with T). Increasing costs of
adverse events common with PLD and reducing costs of
adverse events common with T gave results still favourable to
PLD, with a cost saving of 1442.85 euros instead of the 2209.97
euros cost saving in the base-case.
(b) Equalising the number of total cycles administered with the
two drugs to 1164 cycles, corresponding to the total cycles in
the PLD arm: as T had a more frequent (and thus more
expensive) administration, results are in its favour, assuming
equal efficacy for the two drugs. Results obtained are still
favourable to PLD, with a cost saving of 1625.39 euros.
(c) Assuming that the antiemetic drugs required to be adminis-
tered concomitantly with topotecan have a zero cost (the
favourable effect of reducing nausea and vomiting is retained
but no cost is incurred), another sensitivity analysis was
carried out. The results show no difference in final outcomes
with a cost saving of 1586.16 euros favouring the treatment
with PLD.
(d) Assuming application of all the above independent changes
that favour T: changing hospitalisation length and number of
outpatient visits (related to management of adverse events),
equalising the number of total cycles required for PLD and T
and considering that the concomitant antiemetic drugs used
with T have a zero cost (related to the cost of study drugs and
their administration). This analysis gave a result which is still
favourable to PLD, with a cost saving of 319.99 euros.
(e) Using lower hypothetical doses for PLD and T. In special
populations, the expert panel recommended a dose of
40mgm
 2 every 28 days for PLD and 1.25mgm
 2day
 1 for
five consecutive days every 21 days for T. Assuming that equal
efficacy still applies to these two lower dose regimens, this
change does not influence the study results with a cost saving
of 3057.62 euros using PLD.
Table 6 shows results from the five sensitivity analyses.
DISCUSSION
Ovarian cancer is the leading cause of cancer deaths of the female
reproductive system. The complex therapy used and the increasing
number of patients make ovarian cancer a potentially expensive
disease to treat, increasing concern to find the most efficient
therapy (Berger et al, 1998).
Table 4 Cost estimation of management of each adverse event (euros)
Adverse event type Grade Costs
Anaemia Grade I 0
Grade II 727.42
Grade III 326.29
Grade IV 542.89
Thrombocytopenia Grade I 0
Grade II 35.35
Grade III 194.17
Grade IV 566.97
Neutropenia Grade I 0
Grade II 0.40
Grade III 149.63
Grade IV 409.53
Sepsis Grade I 0
Grade II 2897.52
Grade III 2897.52
Grade IV 2897.52
Fever Grade I 0
Grade II 131.84
Grade III 142.03
Grade IV 797.26
Stomatitis/pharyngitis Grade I 0
Grade II 106.90
Grade III 724.45
Grade IV 1330.53
Nausea/vomiting Grade I 0.02
Grade II 0.43
Grade III 356.61
Grade IV 1118.9
Diarrhoea Grade I 0
Grade II 51.19
Grade III 484.22
Grade IV 1064.01
PPE Grade I 0
Grade II 46.11
Grade III 168.36
Grade IV 1036.00
PPE¼palmar-plantar erythrodysesthesia.
Table 5 Costs of drug, administration and management of adverse
events per patient (euros). Final results of the economic analysis
PLD Topotecan Difference
Total cost: drug+administration 8647.70 8519.94 127.76
Drug cost 7785.43 4256.66
Administration cost 862.27 4263.29
Total cost adverse events 967.02 3304.75  2337.73
Anaemia 334.25 1687.19
Thrombocytopenia 4.51 337.51
Neutropenia 45.32 859.82
Sepsis 48.49 209.61
Fever 15.53 36.41
Stomatitis/pharyngitis 163.94 23.00
Nausea/vomiting 69.48 115.84
Diarrhoea 210.01 35.37
PPE 75.49 0.00
Total cost 9614.72 11824.69  2209.97
PLD¼pegylated liposomal doxorubicin hydrochloride; PPE¼palmar-plantar ery-
throdysesthesia.
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lThis cost-minimisation study has examined the total costs
associated with treatment with PLD and T in patients with
recurrent epithelial ovarian cancer who failed a first-line platinum-
containing regimen. This analysis reveals that total costs of drug
and administration per patient do not differ substantially between
the two drugs. However, the total medical costs are lower for PLD,
due to the additional costs associated with management of adverse
events required during treatment with T. Sensitivity analysis
showed that the outcomes of our analysis were robust, since
changes to variables that favour T were made without changing the
results substantially. Even when considering all the assumptions
that favour topotecan and bringing them together in the same
analysis, the strategy with PLD has a lower cost.
Some limitations of the study must be considered when
evaluating the results obtained. Data on which we have based
our analysis came from an efficacy study, with an absence of
effectiveness data (data in real clinical practice). In addition,
resource utilisation was determined using expert opinion. The
ideal design for the assessment of medical resource utilisation in
this cost-minimisation analysis would have been an observational
design, with a prospective economic appraisal to determine
resource utilisation; however, time constraints did not allow the
execution of this type of study.
Although lower doses might be used in special cases, frequency
or severity of adverse events could change (Smith et al, 2002).
Despite considering lower doses of both drugs according to the
expert panel recommendation and assuming equivalent efficacy
(not clearly supported by bibliography), sensitivity analysis results
remain unaffected and verify the robustness of the model. The
impact of direct nonmedical costs and indirect costs were not
included, dealing only with direct medical costs. Broader issues of
outcomes such as productivity loss or intangible benefits may
show differences between the two drugs that were not captured in
our analysis. Thus, normally asymptomatic neutropenia does not
represent a loss in productivity, but there might be lost time from
work due to PPE or stomatitis with PLD. However, if the costs of
time-off-work and patient-related costs of travel and waiting time
are considered, the analysis would favour PLD, as it is
administered once monthly instead of the 5-day cycle every 3
week T treatment.
Quality of life and patients preferences have not been considered
in our analysis, and these are important measures in the cancer
field, where quantity and quality of life has a high importance.
Incorporation of these parameters may affect the results, especially
since both administration and incidence of adverse events differ
between the two drugs. A cost–utility analysis would have been
more interesting, associating costs and quality of life derived from
each therapy, and giving patient preferences for each of the two
drugs (Earle et al, 2000).
Adverse events have been discussed by experts giving the
Spanish point of view in usual clinical practice, excluding some
events reported in the clinical trial such as alopecia (with a greater
percentage in the topotecan group) because it is not routinely
treated at hospitals. Adverse event management is different
between countries, in terms of choice of drugs, basic treatment
pathway, rates of consultations, etc. The analysis cannot be
extrapolated to other countries because of these differences.
In summary, on the basis that PLD has overall comparable
efficacy with topotecan, a cost-minimisation analysis was per-
formed arriving at the conclusion that PLD is an efficient choice
and can be used to reduce costs of treatment in patients with
recurrent epithelial ovarian cancer who failed a first-line platinum-
containing regimen.
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